Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 88 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Midazolam Infusion Clear all

Conditions: Pain, Postoperative
Interventions: Fentanyl; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis (UC), Crohn's Disease
Interventions: Risankizumab, Cytochrome P450 (CYP) Substrates; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Coronado, California • DeLand, Florida • Margate, Florida + 1 more

Conditions: Transcatheter Aortic Valve Replacement (TAVR), Aortic Valve Stenosis
Interventions: Propofol, Dexmedetomidine, Midazolam, Fentanyl; Drug
Lead sponsor: David Lyubashevsky; Other
Eligibility: 18 Years to 90 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Chronic Kidney Disease
Interventions: AZD4248, Placebo, Midazolam, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sleep Deprivation, Delirium
Interventions: Dexmedetomidine, Placebo; Drug · Other
Lead sponsor: Maisonneuve-Rosemont Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Collapse of Thoracic Vertebra, Collapse of Lumbar Vertebrae
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bronchoscopy
Interventions: Remifentanil, Fentanyl, Midazolam, Ketamine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mechanical Ventilation, Respiratory Failure
Interventions: Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects, Protocol Directed Sedation and Daily Sedation Interruption; Other
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions: Nitrous Oxide, Midazolam; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Complex Regional Pain Syndrome
Interventions: Ketamine, IV NSS, Normal Saline; Drug · Other
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Fatigue
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract
Interventions: dexmedetomidine, Propofol, Dexemedetomidine; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Bipolar Disorder
Interventions: ketamine, midazolam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Laparoscopic Gastric Bypass Surgery, Ketamine
Interventions: Ketamine, Standard therapy; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 69 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Ketamine Hydrochloride, Midazolam injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Refractory Status Epilepticus
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mechanical Ventilation, Critical Illness
Interventions: Dexmedetomidine, Propofol, Fentanyl, Midazolam, Physical and Occupational Therapy; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions: Ketamine Hydrochloride, Midazolam Hydrochloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more

Conditions: Stroke
Interventions: Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 90 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Louisville, Kentucky + 6 more

Conditions: Seizures, Encephalopathy
Interventions: EEG monitoring and treatment of EEG seizures; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Hour to 72 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: PharmaTher Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more

Search by objective public record fields.

Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Patient Quality of Recovery After TAVR With Different Sedation Regimens

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

Understanding How Ketamine Brings About Rapid Improvement in OCD

Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

Study of Dexmedetomidine in Spine Surgery

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

Analgesia-First Sedation in Trauma Patients

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS

Ketamine for Treatment of MS Fatigue

Dexmedetomidine vs. Propofol for Cataract Surgery

Treatment Study of Bipolar Depression

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Perioperative Ketamine for Pain With Gastric Bypass

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Ketamine for the Treatment of Refractory Status Epilepticus

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

Ketamine for Methamphetamine Use Disorder

SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia